MedTrace Logo

AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects

NCT02163161 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-08-18

No results posted yet for this study

Summary

Phase 1, open label, single dose, 3 way crossover study to evaluate the bioavailability of a solid dose formulation of PF 04965842 relative to a suspension formulation under fasting conditions and the effect of food on the bioavailability of the solid dosage formulation of PF 04965842 in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

PF-04965842

Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions

DRUG

PF-04965842

Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions

DRUG

PF- 04965842

Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02163161 on ClinicalTrials.gov